ENYO Pharma is a privately held biopharmaceutical company with an innovative approach inspired by viruses. Our biotech mimics virus strategy to modulate host cellular functions with multiple applications.
ENYO Pharma develops new drug candidates in multiple indications such as infectious diseases (e.g. HBV), metabolic diseases (e.g. NASH) and oncology.
ENYO Pharma was founded in 2014 & is based in Lyon, France and in Melbourne, Australia. Lyon, France and in Melbourne, Australia.
ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules.
ENYO Pharma is pioneering a brand new approach and has built a unique drug discovery engine based on biomimetism of the secular strategy how viruses have adapted during evolution to hijack the human cellular functions for their own benefit.
ENYO Pharma owns an exhaustive database of all known virus/human protein-protein interactions from which new cellular targets are discovered. From that, small active molecules are designed and developed until Phase II clinical trials internally or through partnerships. The company is currently developing treatments against metabolic diseases, infectious diseases and in oncology.
ENYO Pharma is backed by leading investors including Bpifrance, OrbiMed, Andera Partners, & Sofinnova Ventures among others.